Zevalin Completes Transition To ASP-Based Reimbursement In OPPS

Spectrum Pharmaceuticals' radiopharmaceutical Zevalin (ibritumomab tiuxetan) will be reimbursed like other Medicare Part B drugs administered in the hospital outpatient setting, according to the final outpatient prospective payment update for 2010